Conclusions
1 evidence topic · 7 sources
Summary
Inaxaplin is an investigational oral APOL1 channel inhibitor for a genetically defined kidney disease for which no targeted therapy is approved. The efficacy evidence available as of November 2026 consists of proteinuria reductions in two open-label, single-arm studies: a mean UPCR change of -47.6% at week 13 in 13 participants with FSGS, and UACR changes of -42.7% and -17.3% at week 13 in the two AMPLIFIED cohorts (analyses of 18 and 14 participants with a week 13 assessment). Reported adverse events were mild or moderate, with headache the most frequent across studies. No randomized efficacy or safety results are available; the AMPLITUDE interim analysis, which Vertex states could support potential U.S. accelerated approval, is expected in early 2027, and the final analysis uses eGFR slope. Inaxaplin has no announced price, no economic evaluation has been published, and treatment would require APOL1 genotyping to identify eligible people.